ClinicalTrials.gg
Enrolling by invitationNCT07677995Updated Sep 1, 2026

Free Fatty Acid Effects In Type 2 Diabetes

An interventional study of Omega-3 Fatty Acids and Semaglutide 0.25 mg in Type 2 Diabetes, Cardiovascular Disease and Omega-3 Fatty Acids, sponsored by University of Ulster. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by University of Ulster · Not applicable, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, none of them phase 3. omega-3 fatty acid · Diabetes Mellitus, Type 2.

Planned enrollment
9th of 14
60 · median 77
Started
2026
with 1 other
No phase
7 of 14
3 open now
Registered
14th of 14
by date

Among the 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2, this one is the 9th largest by planned enrollment, is one of 2 that started in 2026, is one of 7 with no phase, and was the 14th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About omega-3 fatty acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omega-3 fatty acid in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Omega-3 fatty acids are natural fats found in foods such as oily fish and flaxseed. Omega-3 fatty acids have been found to have positive effects on cardiovascular health, but there is less evidence on if they can help manage blood glucose in individuals with both cardiovascular disease and type 2 diabetes.

This study will investigate whether the beneficial effects found in omega-3 fatty acids such as lowered blood glucose and reduced inflammation - both of which are important for managing type 2 diabetes and cardiovascular disease, can be beneficial for individuals with type 2 diabetes. As omega-3 fatty acids are already found naturally in food, and are already available as supplements, they could be a safe option to help manage these diseases.

The aim of this study is to investigate if omega-3 fatty acids can slow down the progression of type 2 diabetes and reduce the risk of cardiovascular disease in individuals with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes
  • Cardiovascular Disease
  • Omega-3 Fatty Acids
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals who are over 18 years of age with a between 25-50 kg/m2, and who have been diagnosed with T2DM (>7.0 mmol/l fasting glucose) or pre-diabetes (impaired glucose tolerant 5.0-6.9mmol/l) and are either on no medication, are diet controlled or taking metformin. Participants may also have a history of cardiovascular disease.

Exclusion criteria

Exclusion Criteria:

  • Those who have severe or unstable cardiovascular disease
  • Type 2 diabetics or prediabetics who are on an anti-diabetic medication (with the exception of metformin)
  • Undergone recent major surgery or planned surgery during the study period
  • Have implanted devices (such as pacemakers or defibrillators)
  • Have an active infection
  • Are involved in any other type of weight loss study/intervention
  • Are pregnant/breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo

  • Experimental
    Omega-3 Fatty Acid Supplementation (EPA/DHA)

    Dietary Supplement: Omega-3 Fatty Acids

  • Experimental
    Omega-3 Fatty Acid Supplementation (ALA)

    Dietary Supplement: Omega-3 Fatty Acids

  • Experimental
    Omega-3 Fatty Acid Supplementation (EPA/DHA) and Semaglutide

    Semaglutide is being used for comparison purposes only

    Dietary Supplement: Omega-3 Fatty Acids · Drug: Semaglutide 0.25 mg

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the change in fasting glucose from baseline after 28 days of treatment, compared to each treatment group and placebo.

    Time frame: From baseline to 28 days of treatment

Secondary outcomes

  1. The change in insulin compared to placebo administration

    Time frame: From baseline to 28 days of treatment

  2. The change in HbA1c compared to placebo administration

    Time frame: From baseline to 28 days of treatment

  3. Glucose tolerance measurements during OGTT compared to placebo administration

    Time frame: From baseline to 28 days of treatment

  4. Area under the curve measurements during OGTT compared to placebo administration

    Time frame: From baseline to 28 days of treatment

  5. Plasma gut hormone concentrations (GLP-1, GIP, PYY, ghrelin, CCK and glucagon) compared to placebo administration

    Time frame: From baseline to 28 days of treatment

  6. Full lipid profile (cardiovascular risk markers) compared to placebo administration

    Time frame: From baseline to 28 days of treatment

  7. Inflammatory and cardiovascular markers compared to placebo administration

    Biomarkers include inflammatory markers (C-reactive protein \[CRP\], pro- and anti-inflammatory cytokines) and cardiovascular risk markers

    Time frame: From baseline to 28 days of treatment

  8. Liver function tests (ALT and AST) compared to placebo administration

    Time frame: From baseline to 28 days of treatment

  9. Body mass index (BMI) compared to placebo administration

    Weight (kg) and height (m) will be combined to report BMI in kg/m\^2

    Time frame: From baseline to 28 days of treatment

  10. Waist-to-hip circumference compared to placebo administration

    Waist circumference (in cm between the lower rib and iliac crest) and hip circumference (in cm at the widest part of the hips/buttocks) will be combined to calculate waist-to-hip circumference

    Time frame: From baseline to 28 days of treatment

  11. Blood pressure compared to placebo administration

    Time frame: From baseline to 28 days of treatment

  12. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index compared to placebo administration

    Insulin resistance will be measured by calculating HOMA-IR using the formula: HOMA-IR = fasting plasma glucose (mg/dL) x fasting plasma insulin/405. Higher values indicate greater insulin resistance. This is a derived continuous index with no fixed minimum or maximum value.

    Time frame: From baseline to 28 days of treatment

  13. Change in Omega-3 Index (EPA and DHA as a percentage of total fatty acids) compared to placebo administration

    Time frame: From baseline to 28 days of treatment

07

Study locations

1 site
  • School of Biomedical Sciences
    Coleraine, County Londonderry BT52 1SA, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 3 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jul 1, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07677995
Lead sponsor
University of Ulster
Responsible party
Sponsor
First posted
Jul 1, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omega-3 fatty acid

Start the discussion